With deals in tow, Roche ends 2019 with five discarded programs
With sales coming in just shy of Wall Street estimates and profit that just beat expectations, Roche capped off 2019 on a high having finally consummated its arduous acquisition of Spark Therapeutics. That buyout was marred with no less than 10 delays due to regulatory concerns about anticompetitive dealmaking. As is the tradition, the company also culled a number of experimental drugs across its pipeline.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.